glp 1 discontinuation Most adults with overweight or obesity discontinue GLP-1 therapy within 2 years New Truveta study highlights patterns

Conn syndrome is caused by excess aldosterone secretion, usually from an adrenal adenoma or bilateral adrenal hyperplasia

But how does semaglutide stack up against the first-ever weight loss medication, phentermine

Bottom line: MeAgain is built for the person living the GLP-1 journey, not just the metrics around it

The Medicines and Healthcare products Regulatory Agency (MHRA) and manufacturers' Summaries of Product Characteristics (SmPCs) consistently advise against using GLP-1 receptor agonists whilst breastfeeding due to insufficient data on excretion into human breast milk and potential effects on nursing infants

doi: 10.1111/1462-2920.14565 56 ZhuY.JamesonE.CrosattiM.SchaferH.RajakumarK.BuggT